Aptevo advances trispecific candidate APVO451; IND-enabling studies expected 1H2027

Aptevo Therapeutics Inc.

Optimizing several trispecific candidates for reliable, scalable manufacturing, a key step toward human testing.
Lead candidate APVO451 to enter IND-enabling studies in 1H2027.
Trispecifics combine three functions: recognize cancer, activate immune cells, overcome tumor defenses.
Aptevo to present additional details at an upcoming international scientific conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.